5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

• Main Authors: Reiko Matsui (Author), Kenichi Suzuki (Author), Tomomi Takiguchi (Author), Makoto Nishio (Author), Takeshi Koike (Author), Toshinobu Hayashi (Author), Takashi Seto (Author), Yuki Kogure (Author), Naoyuki Nogami (Author), Kimiko Fujiwara (Author), Hiroyasu Kaneda (Author), Tomohiko Harada (Author), Satoru Shimizu (Author), Masashi Kimura (Author), Hirotsugu Kenmotsu (Author), Mototsugu Shimokawa (Author), Koichi Goto (Author)
• Format: Book
• Published: BMC, 2020-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Of patients receiving moderate emetic risk chemotherapy (MEC), 30-90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. Methods In this multicenter, prospective, observational study of adults treated with...